Autologous peripheral blood progenitor cell transplantation

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Autologous peripheral blood stem cell (PBSC) collection is crucial for high-dose chemotherapy regimens.
• Recombinant growth factors, like granulocyte (G)-CSF or granulocyte-macrophage (GM)-CSF, enhance PBSC mobilization.
• Apheresis should ideally occur before significant stem cell toxicity from agents like alkylating agents.

Purpose of the Study:

• To review the current strategies and technologies for harvesting autologous PBSCs.
• To discuss the role of CD34+ cell enumeration as a surrogate marker for stem cell engraftment.
• To explore challenges and future directions in PBSC transplantation.

Main Methods:

• Utilizes efficient apheresis technology for PBSC collection.
• Employs recombinant growth factors (G-CSF/GM-CSF) to stimulate stem cell release.
• Relies on CD34+ cell enumeration to assess stem cell potency and predict engraftment.

Main Results:

• High-dose chemoradiotherapy with PBSC rescue leads to faster engraftment than bone marrow transplantation (BMT).
• CD34+ cell count serves as a reliable index for long-term hematopoietic reconstitution.
• Tumor cell contamination in mobilized PBSCs is a concern, with ongoing research into purification methods.

Conclusions:

• Autologous PBSC transplantation is an effective strategy for treating malignancies, offering rapid engraftment.
• CD34+ cell enumeration is vital for guiding stem cell collection and transplantation protocols.
• Future research focuses on ex vivo expansion, alternative stem cell sources, and gene therapy for enhanced outcomes.